ELMED Life Sciences makes probiotic products for healthcare and agri-biotech companies, and it has now raised $2.7 million in Series A funding from NABVENTURES-managed AgriSURE Fund. It’s chasing a simple but messy problem: reliable microbiome products are still hard to manufacture across human health, animal health, aquaculture, and agriculture. Founded in 2018 by VIT alumni Pruthivin Reddy Madduri and Nikhil Konkathi, the Hyderabad company plans to use the fresh capital to expand production capacity in the city. It also wants to deepen microbiome-focused R&D and push harder into Tier II and Tier III India as well as overseas markets.
That’s a meaningful step for a company in a less flashy part of the business. ELMED isn’t selling a wellness story first. It’s building the formulations and manufacturing backbone that let other brands and healthcare businesses sell probiotic products at all.
What does ELMED Life Sciences actually make?
ELMED Life Sciences is a probiotic manufacturer and formulation partner. It works across human health, animal health, aquaculture, and agriculture. Its business spans contract manufacturing and research and development services for outside companies. Its catalog covers multiple dosage forms and use cases rather than one narrow gut-health SKU.
The human-health side is especially broad. ELMED sells probiotics in vials, capsules, sachets, syrups, and drops, with product examples built around strains such as Bacillus clausii, Bacillus coagulans, Bacillus subtilis, and Saccharomyces boulardii. Some listings are very specific. Triogermila is a 6 billion CFU oral suspension. Endogermila is a Bacillus clausii vial product, and Bacimed is a syrup based on Bacillus subtilis CU1.
That format flexibility matters for customers. A pharma or healthcare brand that wants a room-temperature probiotic in orange-flavored vials has a different manufacturing need from an aquaculture buyer that wants a bacillus-and-pediococcus blend for Vibrio control. An agriculture buyer may be looking for microbial products aimed at soil and water hygiene. ELMED already shows all of those in-market formats, including aquaculture products like VIBRICON and agriculture products like ELTOX.
Taken together, the product catalog points to a practical workflow: strain-led formulation work, dosage-form selection, then scaled manufacturing under one roof. That’s the pitch. Instead of a brand stitching together R&D and production from different vendors, ELMED is trying to collapse that into a single specialist partner. It serves 150+ clients, supports 250+ brands, exports to 18+ countries, and holds 15+ global certifications.
Who founded ELMED Life Sciences and what’s its edge?
The founding story
ELMED was founded in 2018 in Hyderabad by Pruthivin Reddy Madduri and Nikhil Konkathi. The company formally dates to December 13, 2018, and both founders have been on the board since launch. The startup began with a focused bet on probiotics rather than a broad nutraceutical sprawl. That matters because probiotic manufacturing is unforgiving on strain stability, quality control, and dosage-form execution.
Both founders are VIT alumni, and the company has kept its manufacturing base in Hyderabad — a city that already has the supplier base, pharma talent, and export muscle needed for a business like this.
Founder market fit
Pruthivin Reddy Madduri brings a slightly unusual profile for this category. His background is in computer science at VIT, followed by graduate study at California State University, Fullerton, and he has described prior exposure to the U.S. healthcare sector before starting ELMED. He isn’t a bench scientist. But it helps explain why ELMED leans into formulation, process, and product architecture instead of just branding.
Public founder detail on Konkathi is thinner, but he has been there since incorporation and is listed as director across company profiles and industry listings. One older profile on the founding team says both founders worked in healthcare companies after their master’s studies before starting up together in Hyderabad.
Traction and early signals
This is not a pre-product story. ELMED is already operating with a commercial catalog, a manufacturing plant in Cherlapalli, and a customer base large enough to matter. It has 150+ clients and 250+ brands across markets, while the source article names Xanum, Hetero Healthcare, Wallace Pharmaceuticals, and Donovan among its top customers. ELMED also exports to more than 18 countries and wants to go deeper into Europe, Asia, and Latin America.
Its facility is built to produce oral suspensions, emulsions, drops, capsules, sachets, and syrups across therapeutic areas for humans, aquatic life, animals, and plants. That breadth is a real signal. Lots of startups talk about microbiome science. Fewer have translated that into multiple commercial form factors.
Fundraising details and competition
The company’s Series A totals $2.7 million, or ₹25.4 crore, from NABVENTURES-managed AgriSURE Fund. ELMED will use the money for more production capacity in Hyderabad. It also plans stronger R&D in microbiome-based solutions and wider distribution across smaller Indian cities while expanding internationally.
Competition is crowded but fragmented. In India, probiotic manufacturing and contract work already includes established names such as Unique Biotech, Sanzyme Biologics, and other specialist manufacturers that compete on fermentation know-how, certifications, and export readiness. The legacy alternative is even tougher: big pharma brands that outsource probiotic production to experienced contract manufacturers with long regulatory track records. ELMED’s differentiator is its cross-sector footprint — one company serving human health, aquaculture, animal health, and agriculture — plus a dosage-form mix that goes beyond capsules into suspensions, emulsions, drops, and farm-use microbial products.
Why does ELMED Life Sciences funding matter?
This round matters because it shifts ELMED from “credible specialist” toward “scaled platform” , if execution holds up. Production capacity in probiotics isn’t a cosmetic upgrade. It decides how many brands a manufacturer can serve, how consistently it can deliver sensitive strains, and whether it can win larger accounts that don’t tolerate supply shocks.
The R&D piece is just as important. Microbiome products get more valuable when a company can tailor strains, delivery formats, and applications to different end markets. Human gut-health products need one kind of evidence and formulation discipline. Aquaculture and agriculture need another. ELMED is trying to own that complexity instead of staying a plain-vanilla bulk producer.
There’s also the investor angle. NABVENTURES backing this round through AgriSURE suggests the thesis isn’t only about consumer wellness. It’s also about applied microbiome science in rural and agricultural settings, where probiotics can move from supplements into productivity and preventive-health tools.
How big is the probiotics and microbiome market?
The market tailwind is real, even if the exact number depends on what you count. IBEF, citing PharmaTrac, said India’s probiotics market reached ₹2,070 crore in 2025 after roughly doubling in five years and growing 22% on a moving annual total basis in May 2025. IMARC’s broader estimate put India’s probiotics market at $2.2 billion in 2024, with projected CAGR of 17.8% from 2025 to 2033.
That gap in estimates isn’t unusual. Some reports focus tightly on probiotic products sold in certain channels. Others include wider food, supplement, and wellness categories. Either way, this isn’t a fringe category anymore.
The global picture is larger still. IMARC estimated the worldwide probiotics market at $71.9 billion in 2025, with a path to $124 billion by 2034. That scale helps explain why ELMED wants deeper exposure to Europe, Asia, and Latin America rather than staying domestic.
Investor behavior backs that up. On May 6, 2025, Mumbai-based gut-health startup The Good Bug raised ₹100 crore to scale microbiome R&D and expand distribution, showing that capital is still flowing into this segment when companies can tie science to commercial demand. Closer to ELMED’s own category, the broader Indian probiotics industry is also benefiting from demand for natural, preventive, and non-antibiotic solutions across both healthcare and agriculture.
Final take on ELMED Life Sciences
ELMED Life Sciences isn’t the loudest startup in microbiome health. That may actually help. It's a building where a lot of the hard value sits — formulation, manufacturing, and cross-category probiotic infrastructure.
Watch whether ELMED can convert this round into faster capacity build-out, deeper R&D, and real distribution wins outside metros without losing quality discipline.
Read how Deccan AI Raises $25M for Post-Training Stack and why enterprises are investing in tools that make AI systems reliable in production.
FAQ
What funding did ELMED Life Sciences raise?
ELMED Life Sciences raised $2.7 million in a Series A round. The investor was NABVENTURES-managed AgriSURE Fund, and the company is putting that money into manufacturing expansion in Hyderabad, microbiome R&D, and market expansion in India and overseas.
What does ELMED Life Sciences sell?
ELMED sells and manufactures probiotic products across human health, animal health, aquaculture, and agriculture. Its catalog includes vials, capsules, sachets, syrups, drops, and farm-use microbial products, with examples built around strains like Bacillus clausii and Saccharomyces boulardii.
Who founded ELMED Life Sciences?
ELMED was founded in 2018 by Pruthivin Reddy Madduri and Nikhil Konkathi, both VIT alumni. Madduri’s profile includes computer science training, graduate study in California, and prior exposure to the U.S. healthcare sector before launching the business in Hyderabad.
Is ELMED Life Sciences a gut-health brand or a biotech manufacturer?
It’s much closer to a biotech manufacturer and contract development partner than a consumer-first gut-health brand. Unlike companies that mainly sell probiotics directly to shoppers, ELMED works behind the scenes on formulation, R&D, and production for healthcare and agri-biotech customers.
